171 related articles for article (PubMed ID: 25296077)
21. Adjuvant therapy for stage II and III colorectal cancer.
de Gramont A; Tournigand C; André T; Larsen AK; Louvet C
Semin Oncol; 2007 Apr; 34(2 Suppl 1):S37-40. PubMed ID: 17449351
[TBL] [Abstract][Full Text] [Related]
22. [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
Yamaguchi T; Fukuda M; Yasui H; Okazaki S; Kubo K; Tanaka M; Une Y; Setoguchi Y; Hanada K; Moriyama S; Tani M; Murakami T; Okuchi Y; Ogiso S; Hata H; Sakata S; Otani T; Yamato T; Ikai I
Gan To Kagaku Ryoho; 2012 Mar; 39(3):389-93. PubMed ID: 22421765
[TBL] [Abstract][Full Text] [Related]
23. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
24. Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer.
Camacho FT; Wu J; Wei W; Kimmick G; Anderson RT; Balkrishnan R
J Med Econ; 2009 Sep; 12(3):238-45. PubMed ID: 19732030
[TBL] [Abstract][Full Text] [Related]
25. Increased mean corpuscular volume of red blood cells in patients treated with capecitabine for advanced breast and colon cancer.
Scarabelli L; Giovanardi F; Gervasi E; Prati G; Pezzuolo D; Scaltriti L
Chemotherapy; 2013; 59(5):369-72. PubMed ID: 24821441
[TBL] [Abstract][Full Text] [Related]
26. Oral treatment of metastatic breast cancer with capecitabine: what influences the decision-making process?
Górnaś M; Szczylik C
Eur J Cancer Care (Engl); 2010 Jan; 19(1):131-6. PubMed ID: 19686351
[TBL] [Abstract][Full Text] [Related]
27. Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer.
Law CC; Fu YT; Chau KK; Choy TS; So PF; Wong KH
Dis Colon Rectum; 2007 Dec; 50(12):2180-7. PubMed ID: 17963003
[TBL] [Abstract][Full Text] [Related]
28. A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homes.
Weaver A; Love SB; Larsen M; Shanyinde M; Waters R; Grainger L; Shearwood V; Brooks C; Gibson O; Young AM; Tarassenko L
Support Care Cancer; 2014 Oct; 22(10):2677-85. PubMed ID: 24771299
[TBL] [Abstract][Full Text] [Related]
29. Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?
Zielinski C; Gralow J; Martin M
Ann Oncol; 2010 Nov; 21(11):2145-2152. PubMed ID: 20332132
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
[TBL] [Abstract][Full Text] [Related]
31. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
32. [Capecitabine--a review of its antitumor activity and toxicity in clinical studies].
Sasaki T; Maeda Y
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1307-13. PubMed ID: 10945031
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
Allegra CJ; Yothers G; O'Connell MJ; Beart RW; Wozniak TF; Pitot HC; Shields AF; Landry JC; Ryan DP; Arora A; Evans LS; Bahary N; Soori G; Eakle JF; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Sharif S; Roh MS; Wolmark N
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26374429
[TBL] [Abstract][Full Text] [Related]
34. Incorporating oral capecitabine into the treatment of breast cancer. Introduction.
Seidman AD; Aapro M
Oncologist; 2002; 7 Suppl 6():1-3. PubMed ID: 12454313
[No Abstract] [Full Text] [Related]
35. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Blum JL; Dieras V; Lo Russo PM; Horton J; Rutman O; Buzdar A; Osterwalder B
Cancer; 2001 Oct; 92(7):1759-68. PubMed ID: 11745247
[TBL] [Abstract][Full Text] [Related]
36. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
[TBL] [Abstract][Full Text] [Related]
38. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Cunningham D; Coleman R
Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
Huang HY; Jiang ZF; Wang T; Zhang SH; Bian L; Cao Y; Wu SK; Song ST
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):850-3. PubMed ID: 22335952
[TBL] [Abstract][Full Text] [Related]
40. Capecitabine: fulfilling the promise of oral chemotherapy.
Hwang JJ; Marshall JL
Expert Opin Pharmacother; 2002 Jun; 3(6):733-43. PubMed ID: 12036413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]